Antril interleukin-1 receptor antagonist: Began Phase II European trial

Synergen Inc. (SYGN), Boulder, Colo. Product: Antril interleukin-1 receptor antagonist Indication: Rheumatoid arthritis Status: Began Phase II European trial in 500 patients; three doses, administere...